Disc Medicine Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, express or implied statements regarding Discs expectations with respect to its Phase 1b/2 clinical studies of DISC-0974 in patients with MF and NDD-CKD patients with anemia, projected
timelines for the initiation and completion of its clinical trials, anticipated timing of release of data, and other clinical activities; and Discs business plans and objectives. The use of words such as, but not limited to,
believe, expect, estimate, project, intend, future, potential, continue, may, might, plan, will,
should, seek, anticipate, or could or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based on Discs current beliefs, expectations and assumptions regarding the future of Discs business, future plans and strategies, clinical results and other future
conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking
statements.
Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not
place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and
uncertainties including but not limited to: the nature, strategy and focus of Disc; Discs plans to research, develop and commercialize its current and future product candidates; the timing of the availability of data from Discs clinical
trials; the timing and anticipated results of Discs preclinical studies and clinical trials and the risk that the results of Discs clinical trials may not be predictive of future results in connection with future studies or clinical
trials and may not support further development and marketing approval; the other risks and uncertainties described in the Risk Factors section of our Annual Report on Form 10-K for the year ended
December 31, 2022, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023, and other documents filed by Disc from time to time with the
SEC, as well as discussions of potential risks, uncertainties, and other important factors in Discs subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its
affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.
Media Contact
Peg Rusconi
Verge Scientific Communications
prusconi@vergescientific.com